

Kindly amend this application as follows:

IN THE CLAIMS:

(For the Examiner's convenience, all of the pending claims are reproduced below. Claims that have not been amended are indicated as "Unchanged".)

37. **(Unchanged)** A method for treating an autoimmune disease in a human, the method comprising administering by nose or mouth to said human an effective amount for treating said disease of a composition comprising a bystander antigen, wherein said bystander antigen is not an autoantigen in said human and wherein said bystander antigen is not an insulin antigen.

38. **(Unchanged)** The method of claim 37 wherein said bystander antigen is specific to an organ or tissue afflicted by immune attack during said disease.

39. **(Unchanged)** A method for treating an autoimmune disease in a human, the method comprising administering by nose or mouth to said human an effective amount for treating said disease of a composition comprising a bystander antigen, wherein said bystander antigen is not an autoantigen, and wherein said bystander antigen is not an insulin antigen.

42. **(Unchanged)** The method of claim 37 wherein said bystander is administered to said human in aerosol form.

43. **(Unchanged)** The method of claim 37 wherein said bystander antigen is administered in a dry powder form.

44. **(Unchanged)** The method of claim 37 wherein said bystander antigen is administered as a saline solution.

45. **(Unchanged)** The method of claim 38 wherein said administration is effective to treat said disease without causing an accompanying decrease in the blood sugar level of said human.

46. **(Unchanged)** The method of claim 38 wherein said disease is Type I diabetes and said bystander antigen is glucagon.

47. **(Unchanged)** A method for treating type I diabetes in a human, the method comprising administering by inhalation to said human an effective amount for treating said Type I diabetes of glutamic acid decarboxylase.

48. **(Unchanged)** A pharmaceutical dosage form for treating an autoimmune disease in a human, the form consisting essentially of:

an effective amount for treating said disease of a bystander antigen;

and

a pharmaceutically acceptable carrier or diluent;

wherein said bystander antigen is not an autoantigen in said human, and wherein said dosage form is contained in an inhaler or nebulizer.

49. **(Unchanged)** The pharmaceutical dosage form of claim 48 wherein said bystander antigen is specific to an organ or tissue afflicted by immune attack during said disease.

52. **(Unchanged)** The pharmaceutical dosage form of claim 49 wherein said dosage form is an aerosol form.

53. **(Unchanged)** The pharmaceutical dosage form of claim 49 wherein said dosage form is a saline solution.

54. **(Unchanged)** The pharmaceutical dosage form of claim 49 wherein said dosage form is a dry powder.

55. **(Unchanged)** The pharmaceutical dosage form of claim 49 wherein said dosage form is effective to treat said autoimmune disease without causing a lowering of the blood sugar level of said human.

56. **(Unchanged)** The pharmaceutical dosage form of claim 48 wherein said disease is selected from the group consisting of Type I diabetes and animal models therefor and said bystander antigen is glucagon.

57. **(Unchanged)** A pharmaceutical dosage form for nasal administration for treating Type I diabetes in a human comprising an effective amount for treating said type I diabetes of glutamic acid decarboxylase and a pharmaceutically acceptable carrier or diluent in an inhaler or nebulizer.

59. **(Unchanged)** The method of claim 37 wherein said bystander antigen is purified.

Cancel claim 60 without prejudice or disclaimer.

60. **(Canceled)** The method of claim 37 wherein said bystander antigen is substantially pure.

61. **(Unchanged)** The method of claim 37 wherein said composition is substantially free of autoantigens.

62. **(Unchanged)** The pharmaceutical dosage form of claim 48 wherein said bystander antigen is purified.

Cancel claim 63 without prejudice or disclaimer.

63. **(Canceled)** The pharmaceutical dosage form of claim 48 wherein said bystander antigen is substantially pure.

64. **(Unchanged)** The pharmaceutical dosage form of claim 48 wherein said composition is substantially free of autoantigens.

65. **(Unchanged)** A method for treating an autoimmune disease in a human, the method comprising administering by nose or mouth to said human an effective amount for treating said disease of a composition comprising a bystander antigen, wherein said bystander antigen is not an antigen to which T-cells which mediate the disease are sensitized, and wherein said bystander antigen is not an insulin antigen.

REMARKS

Reconsideration of this application is respectfully requested.